| 4.08 0.36 (9.68%) | 06-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.61 | 1-year : | 6.48 |
| Resists | First : | 4.8 | Second : | 5.55 |
| Pivot price | 4.34  |
|||
| Supports | First : | 3.59 | Second : | 2.99 |
| MAs | MA(5) : | 4.05 |
MA(20) : | 4.43 |
| MA(100) : | 5.18 |
MA(250) : | 5.08  |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 15.8 |
D(3) : | 21.1 |
| RSI | RSI(14): 44.3 |
|||
| 52-week | High : | 8.98 | Low : | 0.62 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ KPRX ] has closed above bottom band by 34.4%. Bollinger Bands are 13% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.1 - 4.12 | 4.12 - 4.14 |
| Low: | 3.76 - 3.79 | 3.79 - 3.82 |
| Close: | 4.04 - 4.08 | 4.08 - 4.12 |
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
Wed, 19 Jun 2024
Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in ... - Quantisnow
Wed, 19 Jun 2024
Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress - Quantisnow
Tue, 18 Jun 2024
Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now? - Yahoo Finance
Sat, 15 Jun 2024
Brian M. Strem Buys 3000 Shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Stock - Defense World
Sat, 15 Jun 2024
Erin Parsons Purchases 5260 Shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Stock - Defense World
Fri, 14 Jun 2024
Kiora Pharmaceuticals exec buys $7.6k in company stock By Investing.com - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 49.2 (%) |
| Shares Short | 67 (K) |
| Shares Short P.Month | 73 (K) |
| EPS | -11.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.96 |
| Profit Margin | 17.5 % |
| Operating Margin | 82.5 % |
| Return on Assets (ttm) | 13.1 % |
| Return on Equity (ttm) | 12.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 5.47 |
| EBITDA (p.s.) | 2.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 7 (M) |
| Levered Free Cash Flow | 4 (M) |
| PE Ratio | -0.35 |
| PEG Ratio | 0 |
| Price to Book value | 0.34 |
| Price to Sales | 0.74 |
| Price to Cash Flow | 1.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|